Pathophysiology
Acute response
In the initial stages of allergy, a type I hypersensitivity reaction against an allergen encountered for the first time and presented by a professional antigen-presenting cell causes a response in a type of immune cell called a TH2 lymphocyte, a subset of T cells that produce a cytokine called interleukin-4 (IL-4). These TH2 cells interact with other lymphocytes called B cells, whose role is production of antibodies. Coupled with signals provided by IL-4, this interaction stimulates the B cell to begin production of a large amount of a particular type of antibody known as IgE. Secreted IgE circulates in the blood and binds to an IgE-specific receptor (a kind of Fc receptor called FcεRI) on the surface of other kinds of immune cells called mast cells and basophils, which are both involved in the acute inflammatory response. The IgE-coated cells, at this stage, are sensitized to the allergen.If later exposure to the same allergen occurs, the allergen can bind to the IgE molecules held on the surface of the mast cells or basophils. Cross-linking of the IgE and Fc receptors occurs when more than one IgE-receptor complex interacts with the same allergenic molecule and activates the sensitized cell. Activated mast cells and basophils undergo a process called degranulation, during which they release histamine and other inflammatory chemical mediators (cytokines, interleukins, leukotrienes, and prostaglandins) from their granules into the surrounding tissue causing several systemic effects, such as vasodilation, mucous secretion, nerve stimulation, and smooth muscle contraction. This results in rhinorrhea, itchiness, dyspnea, and anaphylaxis.
There are six varieties of asbestos; the most common variety in manufacturing, white asbestos, is in the serpentine family. Serpentine minerals are sheet silicates; although not in the serpentine family, talc is also a sheet silicate, with two sheets connected by magnesium cations. The frequent co-location of talc deposits with asbestos may result in contamination of mined talc with white asbestos, which poses serious health risks when dispersed into the air and inhaled. Stringent quality control since 1976, including separating cosmetic- and food-grade talc from "industrial"-grade talc, has largely eliminated this issue, but it remains a potential hazard requiring mitigation in the mining and processing of talc. A 2010 US FDA survey failed to find asbestos in a variety of talc-containing products. A 2018 Reuters investigation asserted that pharmaceuticals company Johnson & Johnson knew for decades that there was asbestos in its baby powder, and in 2020 the company stopped selling its baby powder in the US and Canada. There were calls for Johnson & Johnsons largest shareholders to force the company to end global sales of baby powder, and hire an independent firm to conduct a racial justice audit as it had been marketed to African American and overweight women. On August 11, 2022, the company announced it would stop making talc-based powder by 2023 and replace it with cornstarch-based powders. The company said the talc-based powder is safe to use and does not contain asbestos.